First Page | Meta Content | |
---|---|---|
Document Date: 2013-07-21 06:09:47Open Document File Size: 603,39 KBShare Result on FacebookCityLondon / /CompanyADP / COX / AstraZeneca AB / A2A / /CountryUnited Kingdom / /Currencypence / / /FacilityCanary Wharf / /IndustryTermtypical equipment / pharmaceutical development / pharmaceutical and biological aspects / pharmaceutical excipients / drug product / manufacturing process elements / quality risk management / chemical compatibility / chemical name / medicinal product / intermediate products / treatment of both chronic and acute diseases / conventional manufacturing techniques / manufacturing sites / chemical / degradation products / manufacturing process / manufactured using conventional manufacturing techniques / /MedicalConditionblisters / PVC-PVDC blisters / Acute Coronary Syndromes / disease / atherosclerosis / PVC/PVDC/Alu blisters / both chronic and acute diseases / ST elevation Myocardial Infarction / stroke / platelet-mediated arterial thrombosis / both thrombus / acute coronary syndrome / blister / non ST elevation Myocardial Infarction / coronary syndrome / myocardial infarction / unstable angina / hypoxic diseases / /MedicalTreatmentthrombolytic therapy / bypass / surgery / /OrganizationEuropean Medicines Agency / European Union / uropa.eu An / European Union EMA / CHMP / /PersonRay Powder / Gonzalo Calvo Rojas / / /Producttalc / polyethylene glycol / clopidogrel / adenosine / mannitol / /ProgrammingLanguageEC / /ProvinceOrStateMichigan / /TechnologyPharmacokinetics / Pharmacodynamics / stem cells / /URLwww.ema / /SocialTag |